OCT 16, 2013 9:00 AM PDT

Keynote: Breast Cancer Genomics and Genetics

C.E. Credits: CE
Speakers
  • Distinguished Professor of Genetics, Scientific Director of Genomics and Bioinformatics, University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center
    Biography
      Dr. Perou is a member of the Lineberger Comprehensive Cancer Center, the Carolina Center for Genome Sciences, and the Scientific Director of the UNC Genomics and Bioinformatics Core Facility. He received his Ph.D. in Cellular and Molecular Biology from the Department of Pathology at the University of Utah (1996) where he cloned and characterized the human Chediak-Higashi Syndrome gene. He next performed his postdoctoral training in the laboratory of David Botstein at Stanford University (1997-2000) where he began his genomic studies of human tumors using DNA microarrays. These genomic analyses resulted in the identification of novel subtypes of human breast tumors that predict patient survival times and response to therapy. Dr. Perou's laboratory at UNC is focused on using genomics, genetics, and animal models to decipher the underlying biology of the molecular subtypes of breast cancer, and then using this biological information to develop therapies that are specifically targeted against each of these distinct subtypes of breast cancer.

    Abstract:

    It is now appreciated that breast cancer is not a single disease, but instead is a spectrum of tumor subtypes with distinct cellular origins, somatic changes and somewhat predictable clinical behaviors. Gene expression data coming from DNA microarrays, and now sequencing-based technologies, has provided additional insights into the biology of breast cancer that has resulted in the development of a number of clinically useful assays. Our work on breast tumors has led to a new molecular taxonomy that identifies at least five subtypes of breast cancers (Luminal A, Luminal B, HER2-enriched, Basal-like and Claudin-low) and a normal breast-like group. Known as the intrinsic subtypes, these groups have revealed critical differences in incidence, survival, metastatic site specificity, and response to treatment. In addition to the intrinsic subtypes, many other important prognostic and predictive gene expression-based profiles have been identified. These tests have lead to the identification of a subset of ER-positive patients that have an extremely good outcome, and thus, for whom adjuvant endocrine therapy alone appears sufficient. Alternatively, the remaining patients/subtypes including Luminal B, HER2-enriched and Basal-like, show significantly worse prognoses, although targeted therapies for HER2+ patients have greatly improved their outcomes. To address the need for the targeting of Luminal B and Basal-like subtypes, genome sequencing approaches are being employed to provide a means of rationally selecting new targeted agents. Other genomics findings with therapeutic potential include the discovery that a subtype of breast cancer (i.e. the Basal-like subtype) shows significant genetic and mRNA expression similarities with Serous Ovarian Cancers; these similarities include TP53 mutation (>85% with almost no other commonly mutated genes), wide spread genomic instability, RB1-deficiency or Cyclin E1 amplification, BRCA1 inactivation, cMYC amplification, and high expression of AKT3. These common genetic/genomic features suggest that drug regimens that are used for Ovarian Cancer (i.e. a taxane and cis/carboplatin regimen) may also be effective on Basal-like breast cancers, which is being tested at a number of sites worldwide. Data from whole exome sequencing of Basal-like cancers will be presented and used as a model of how genome sequencing can contribute to the identification of potentially targetable driver mutations.


    Show Resources
    You May Also Like
    SEP 05, 2019 4:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 4:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    NOV 18, 2019 7:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 7:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    Loading Comments...
    Show Resources